ClinicalTrials.gg
CompletedNCT00743340Updated Apr 26, 2018Results posted

Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine

A Phase 2 interventional study of Emtricitabine in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 2 sites in South Africa. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2018-04-26.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Other

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Nov 2005, registered Aug 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
1 Month to 17 Years
Sex
All
01

Study summary

The primary objectives of this trial are to provide FTC-203 study participants in South Africa with continued access to the study drug, emtricitabine (FTC), following completion of the FTC-203 study and to collect long-term safety information in participants receiving emtricitabine in combination with other antiretroviral agents.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • HIV-1 infection
  • emtricitabine
  • pediatrics
  • pediatric patients
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Complete or have previously completed at least through the Week 96 Visit (i.e., 96 weeks on study) for the FTC-203 study.
  • Complete all End-of-Study Visit procedures for the FTC-203 study.
  • Either (a) have a plasma -1 RNA viral load of ≤ 400 copies/mL at the End-of-Study Visit for the FTC-203 study, or (b) if the subject's plasma HIV-1 RNA viral load at the End-of-Study Visit for FTC-203 study is > 400 copies/mL, their viral load is \< 1.0 log10 above the nadir recorded after Week 8 of the FTC-203 study and there is reliable genotypic evidence showing a lack of resistance to emtricitabine.
  • A parent or other legal guardian has provided written to the subject participating in the rollover protocol. As applicable, based on the subject's age and normal institution practice, the subject should additionally provide their written informed consent or assent to participate in the rollover protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Emtricitabine

    Participants will receive emtricitabine for as long as they continue to meet specific virologic criteria and until either: (1) the participant chooses to discontinue treatment of emtricitabine and withdraw from the rollover protocol; (2) the participant experiences a toxicity that necessitates the permanent discontinuation of emtricitabine, or (3) emtricitabine is approved for market distribution in the participant's country of residence.

    Drug: Emtricitabine

Interventions

  • 6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Had Access to, and Received the Intervention

    This endpoint has been included to satisfy the requirements of ClinicalTrials.gov. However, there were no prespecified endpoints in this study.

    Time frame: Up to 586 weeks

07

Results

Posted Apr 26, 2018

Participant flow

Participants were enrolled at 2 study sites in South Africa. The first participant was screened on 22 November 2005. The last study visit occurred on 13 February 2017.

Participant flow — Overall Study
MilestoneEmtricitabine
Started50
Completed9
Not completed41
Withdrew: Study medication non-compliance1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal from the study5
Withdrew: Protocol violation1
Withdrew: Virologic failure8
Withdrew: Pregnancy1
Withdrew: Rolled over to other gilead study23
Withdrew: Participant relocated1

Outcome measures

PrimaryNumber of Participants Who Had Access to, and Received the Intervention

This endpoint has been included to satisfy the requirements of ClinicalTrials.gov. However, there were no prespecified endpoints in this study.

Time frame:
Up to 586 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Had Access to, and Received the Intervention
ParticipantsEmtricitabine
Number of Participants Who Had Access to, and Received the Intervention50

Adverse events

Collected over Up to 586 Weeks + 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Emtricitabine0/50 (0%)13/50 (26%)0/50 (0%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventEmtricitabine
Lower limb fractureInjury, poisoning and procedural complications2/50
AppendicitisInfections and infestations2/50
Essential hypertensionVascular disorders1/50
Femur fractureInjury, poisoning and procedural complications1/50
Hand fractureInjury, poisoning and procedural complications1/50
OverdoseInjury, poisoning and procedural complications1/50
Weight decreasedInvestigations1/50
BronchospasmRespiratory, thoracic and mediastinal disorders1/50
AnaemiaBlood and lymphatic system disorders1/50
NeutropeniaBlood and lymphatic system disorders1/50

Baseline characteristics

Safety Analysis Set: all enrolled participants who have received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Emtricitabine
Mean8 ± 2.5
Sex: Female, Male
Sex: Female, Male(Participants)Emtricitabine
Female24
Male26
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Emtricitabine
Black49
Other1
08

Study locations

2 sites
  • Themba Lethu Clinic, Helen Joseph Hospital, Westdene
    Johannesburg, South Africa
  • Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital
    Soweto, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2005 to primary completion in Feb 2017, 134 months.

Results were first posted in Apr 2018, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2008
First posted
Aug 28, 2008
StartActual
Nov 22, 2005
Primary completionActual
Feb 13, 2017
CompletionActual
Feb 13, 2017
Results first posted
Apr 26, 2018
Last update
Apr 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00743340
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 28, 2008
Start date
Nov 22, 2005
Primary completion
Feb 13, 2017
Completion
Feb 13, 2017
Results posted
Apr 26, 2018
Last update
Apr 26, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emtricitabine

Start the discussion